The findings suggest that lysozomal storage abnormalities in Niemann-Pick disease patients may impact the hypothalamus and, more specifically, hypocretin-containing cells. These changes might be partially responsible for sleep abnormalities and cataplexy in patients with Niemann-Pick disease.

No abstract

The article presents the results of studies on the effectiveness and safety of a III generation calcium antagonist lercanidipine in the treatment of hypertension. Lercanidipine treatment leads to a marked significant reduction in systolic and diastolic blood pressure without producing a significant effect on heart rate. The drug has organ-protective effect, reduces left ventricular hypertrophy, improves kidney function and has antiproteinuric action. Lercanidipine is well tolerated, less likely to cause peripheral edema compared with other calcium antagonists.

Diuretics have been long used to treat arterial hypertension; however, the use of loop diuretics has been limited by cases of chronic kidney and heart failure. The loop diuretic torasemide is now administered in subdiuretic doses (2,5–5 mg) to treat arterial hypertension; it is well tolerated, metabolically neutral, and, due to its antialdosterone effect, fails to cause hypokalemia.

The article deals with the use of calcium antagonists (CA) with a focus on diltiazem for the treatment of hypertension, angina pectoris, and cardiac arrhythmias, for secondary prevention of coronary heart disease, to evaluate their cardiac, angiography, nephroprotective effect, the ability to prevent the development of left ventricular hypertrophy. The problems of tolerability and safety of CA in short and prolonged action.